Baron Rudi A, Casey Patrick J
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA.
BMC Biochem. 2004 Dec 29;5:19. doi: 10.1186/1471-2091-5-19.
Isoprenylcysteine carboxyl methyltransferase (Icmt) is the third of three enzymes that posttranslationally modify proteins that contain C-terminal CaaX motifs. The processing of CaaX proteins through this so-called prenylation pathway via a route initiated by addition of an isoprenoid lipid is required for both membrane targeting and function of the proteins. The involvement of many CaaX proteins such as Ras GTPases in oncogenesis and other aberrant proliferative disorders has led to the targeting of the enzymes involved in their processing for therapeutic development, necessitating a detailed understanding of the mechanisms of the enzymes.
In this study, we have investigated the kinetic mechanism of recombinant human Icmt. In the reaction catalyzed by Icmt, S-adenosyl-L-methionine (AdoMet) provides the methyl group that is transferred to the second substrate, the C-terminal isoprenylated cysteine residue of a CaaX protein, thereby generating a C-terminal prenylcysteine methyl ester on the protein. To facilitate the kinetic analysis of Icmt, we synthesized a new small molecule substrate of the enzyme, biotin-S-farnesyl-L-cysteine (BFC). Initial kinetic analysis of Icmt suggested a sequential mechanism for the enzyme that was further analyzed using a dead end competitive inhibitor, S-farnesylthioacetic acid (FTA). Inhibition by FTA was competitive with respect to BFC and uncompetitive with respect to AdoMet, indicating an ordered mechanism with SAM binding first. To investigate the order of product dissociation, product inhibition studies were undertaken with S-adenosyl-L-homocysteine (AdoHcy) and the N-acetyl-S-farnesyl-L-cysteine methylester (AFCME). This analysis indicated that AdoHcy is a competitive inhibitor with respect to AdoMet, while AFCME shows a noncompetitive inhibition with respect to BFC and a mixed-type inhibition with respect to AdoMet. These studies established that AdoHcy is the final product released, and that BFC and AFCME bind to different forms of the enzyme.
These studies establish that catalysis by human Icmt proceeds through an ordered sequential mechanism and provide a kinetic framework for analysis of specific inhibitors of this key enzyme.
异戊二烯基半胱氨酸羧基甲基转移酶(Icmt)是三种对含有C末端CaaX基序的蛋白质进行翻译后修饰的酶中的第三种。通过这种所谓的异戊二烯化途径,经由添加类异戊二烯脂质启动的路线对CaaX蛋白进行加工,对于蛋白质的膜靶向和功能而言是必需的。许多CaaX蛋白,如Ras GTP酶参与肿瘤发生和其他异常增殖性疾病,这导致了针对其加工过程中涉及的酶进行治疗性开发,因此需要详细了解这些酶的作用机制。
在本研究中,我们研究了重组人Icmt的动力学机制。在Icmt催化的反应中,S-腺苷-L-甲硫氨酸(AdoMet)提供甲基,该甲基转移至第二种底物,即CaaX蛋白的C末端异戊二烯化半胱氨酸残基,从而在蛋白质上生成C末端异戊烯基半胱氨酸甲酯。为便于对Icmt进行动力学分析,我们合成了该酶的一种新的小分子底物,生物素-S-法尼基-L-半胱氨酸(BFC)。Icmt的初始动力学分析表明该酶的反应机制为有序机制,使用终产物竞争性抑制剂S-法尼基硫代乙酸(FTA)进行了进一步分析。FTA的抑制作用相对于BFC是竞争性的,相对于AdoMet是非竞争性的,表明是一种先结合SAM的有序机制。为研究产物解离的顺序,用S-腺苷-L-高半胱氨酸(AdoHcy)和N-乙酰-S-法尼基-L-半胱氨酸甲酯(AFCME)进行了产物抑制研究。该分析表明AdoHcy相对于AdoMet是竞争性抑制剂,而AFCME相对于BFC表现出非竞争性抑制,相对于AdoMet表现出混合型抑制。这些研究确定AdoHcy是最终释放的产物,并且BFC和AFCME与酶的不同形式结合。
这些研究确定人Icmt的催化作用通过有序顺序机制进行,并为分析该关键酶的特异性抑制剂提供了动力学框架。